References
- Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352, 2285–2293 (2005).
- International Warfarin Pharmacogenetics Consortium. Improved warfarin dosing with a global pharmacogenetic algorithm. N. Engl. J. Med.360, 753–764 (2009).
- Hillman MA, WIlke RA, Yale Sh et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res.3, 137–145 (2005).
- Anderson JL, Horne BD, Steves SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116, 2563–2570 (2007).
- Caraco Y, Blotnick S, Muszak M et al.CYP2C9 genotype-guided warfarin prescribing enchances the efficacy and safety of anticoagulation, a prospective randomized controlled study. Clin. Pharmacol. Ther.93, 467–470 (2008).
- Eckman MH, Rosand J, Greenberg SM et al. Cost–effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med.150, 73–83 (2009).
- Wu AHB, Babic N, Yeo JT. Implementation of pharmacogenomics into the clinical practice of therapeutics, issues for the clinician and the laboratorian. Person. Med.6, 315–327 (2009).
- Flockhart DA, O’Kane D, Williams MS, Watson MS. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med.10, 139–150 (2008).
- Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Amercian College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest133, S160–S198 (2008).
- Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy28, 1084–1097 (2008).
- Peterson P, Hayes T, Arkin C et al. The preoperative bleeding time test lacks clinical benefit. College of American Pathologists and American Society of Clinical Pathologists position article. Arch. Surg.133, 134–139 (1998).
- Wu AHB, Gross S. Response to tips from the clinical experts. Med. Lab. Observ.38(2), 6–8 (2006).
- Craven LL. Acetyl salicylic acid, possible prevention of coronary thrombosis. Ann. Western Med. Surg.4, 95–99 (1950).
- Morrow DA, Cannon CP, Rifai N et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction, results from a randomized trial. JAMA286, 2405–2412 (2001).
- Takeuch F, McGinnis R,Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet.5, e1000433 (2009).
- Teagarden JR. Warfarin and pharmacogenomic testing, what would Pascal do? Pharmacotherapy29, 245–247 (2009).
- Woodcock J, Lesko LJ. Pharmacogenetics-tailoring treatment for the outliers. N. Engl. J. Med.360, 811–813 (2009).
- Pegels CC, Seagle JP. A note on the hidden added costs of RIA test adoption. Transfusion13, 154–155 (1973).
- Eckman MH, Rosand J, Greenbert SM, Gage BF. Cost–effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med.150, 73–83 (2009).
Websites
- Machalek A. Could genetics improve warfarin dosing www.nigms.nih.gov/News/Results/Warfarin02182009.htm (Accessed 18 February 2009)
- Lesko L, Regulatory science at the US FDA, integrating scientific advances into the product label www.aacc.org/members/nach/LMPG/OnlineGuide/DraftGuidelines/Pharmacogenetics/Pages/default.aspx
- Use of genetic testing to guide the initiation of warfarin therapy. A technology assessment. California Technology Assessment Forum www.ctaf.org/content/assessment/detail/814 (Accessed 5 May 2008)
- Centers for Medicare & Medicaid Services. Decision memo for pharmacogenomic testing for warfarin response (CAG-00400N) www.cms.hhs.gov/mcd/viewdecisionmemo.asp?from2=viewdecisionmemo.asp&id=224& (Accessed 3 August 2009)